NCT03754790
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
Registry fields
- Overall status
- COMPLETED
- Conditions
- Hemophilia
- Study type
- INTERVENTIONAL
- Phase
- PHASE3
- Primary purpose
- TREATMENT
- Intervention type
- DRUG
- Interventions
- Fitusiran
- Lead sponsor
- Genzyme, a Sanofi Company (INDUSTRY)
Cached at: 2026-10-01 04:05:12
Brief summary
Primary Objective:
To characterize the long-term safety and tolerability of fitusiran
Secondary Objectives:
* To characterize the efficacy and long-term efficacy of fitusiran as assessed by the frequency of:
* Bleeding episodes
* Spontaneous bleeding episodes
* Joint bleeding episodes
* To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants ≥17 years of age
To characterize the long-term safety and tolerability of fitusiran
Secondary Objectives:
* To characterize the efficacy and long-term efficacy of fitusiran as assessed by the frequency of:
* Bleeding episodes
* Spontaneous bleeding episodes
* Joint bleeding episodes
* To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants ≥17 years of age
Contact
Need a report or Korean medical writing based on this trial?
Sign in with Kakao to continue